Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F S Tjoeng

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
International Journal of Peptide and Protein Research|February 1, 1990
Multiple peptide synthesis using a single support (MPS3)F S Tjoeng, D S Towery, J W Bulock, et al.
European Journal of Pharmacology|January 24, 1995
Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthaseJ R Connor, P T Manning, S L Settle, et al.
Bioorganic & Medicinal Chemistry|May 1, 1995
A novel series of orally active antiplatelet agentsJ A Zablocki, F S Tjoeng, P R Bovy, et al.
Thrombosis Research|June 1, 1994
SC-49992--a potent and specific inhibitor of platelet aggregationN S Nicholson, S G Panzer-Knodle, L W King, et al.
Journal of Medicinal Chemistry|June 23, 1995
Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (Aminobenzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonistsJ A Zablocki, J G Rico, R B Garland, et al.
Bioorganic & Medicinal Chemistry|September 1, 1994
Design of orally active, non-peptide fibrinogen receptor antagonists. An evolutionary process from the RGD sequence to novel anti-platelet aggregation agentsP R Bovy, F S Tjoeng, J G Rico, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1991
Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749)N S Nicholson, S G Panzer-Knodle, A K Salyers, et al.
Journal of Medicinal Chemistry|February 2, 1996
2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoformsW M Moore, R K Webber, K F Fok, et al.
FEBS Letters|November 30, 1987
Phosphorylation of high- and low-molecular-mass atrial natriuretic peptide analogs by cyclic AMP-dependent protein kinaseG M Olins, P P Mehta, D J Blehm, et al.
Thrombosis Research|June 1, 1991
In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agentN S Nicholson, S G Panzer-Knodle, A K Salyers, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
International Journal of Peptide and Protein Research|February 1, 1990
Multiple peptide synthesis using a single support (MPS3)F S Tjoeng, D S Towery, J W Bulock, et al.
European Journal of Pharmacology|January 24, 1995
Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthaseJ R Connor, P T Manning, S L Settle, et al.
Bioorganic & Medicinal Chemistry|May 1, 1995
A novel series of orally active antiplatelet agentsJ A Zablocki, F S Tjoeng, P R Bovy, et al.
Thrombosis Research|June 1, 1994
SC-49992--a potent and specific inhibitor of platelet aggregationN S Nicholson, S G Panzer-Knodle, L W King, et al.
Journal of Medicinal Chemistry|June 23, 1995
Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (Aminobenzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonistsJ A Zablocki, J G Rico, R B Garland, et al.
Bioorganic & Medicinal Chemistry|September 1, 1994
Design of orally active, non-peptide fibrinogen receptor antagonists. An evolutionary process from the RGD sequence to novel anti-platelet aggregation agentsP R Bovy, F S Tjoeng, J G Rico, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1991
Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749)N S Nicholson, S G Panzer-Knodle, A K Salyers, et al.
Journal of Medicinal Chemistry|February 2, 1996
2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoformsW M Moore, R K Webber, K F Fok, et al.
FEBS Letters|November 30, 1987
Phosphorylation of high- and low-molecular-mass atrial natriuretic peptide analogs by cyclic AMP-dependent protein kinaseG M Olins, P P Mehta, D J Blehm, et al.
Thrombosis Research|June 1, 1991
In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agentN S Nicholson, S G Panzer-Knodle, A K Salyers, et al.
Pageof 3